CD55 Antikörper

Produktnummer ABIN2192214

Dieses Anti-CD55-Antikörper ist ein Ratte Monoklonal-Antikörper zur Detektion von CD55 in WB und FACS. Geeignet für Maus. Dieses Primary Antibody wurde in 4+ Publikationen zitiert.

Kurzübersicht für CD55 Antikörper (ABIN2192214)

Target: CD55 (Complement Decay-Accelerating Factor (CD55))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser CD55 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Flow Cytometry (FACS)

Klon: 3D5

Produktdetails anti-CD55 Antikörper

Sterilität: 0.2 μm filtered

Anwendungsinformationen

Applikationshinweise: It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Haltbarkeit: 12 months

Referenzen für anti-CD55 Antikörper (ABIN2192214)

Lin, Fukuoka, Spicer, Ohta, Okada, Harris, Emancipator, Medof: "Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies." in: Immunology, Vol. 104, Issue 2, pp. 215-25, (2001) (PubMed).

Harris, Spiller, Morgan: "Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities." in: Immunology, Vol. 100, Issue 4, pp. 462-70, (2000) (PubMed).

Spiller, Goodfellow, Evans, Almond, Morgan: "Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF." in: The Journal of infectious diseases, Vol. 181, Issue 1, pp. 340-3, (2000) (PubMed).

Spiller, Harris, Morgan: "Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells." in: Journal of immunological methods, Vol. 224, Issue 1-2, pp. 51-60, (1999) (PubMed).

Details zu CD55

Target: CD55 (Complement Decay-Accelerating Factor (CD55))

Andere Bezeichnung: Complement Decay Accelerating Factor

Hintergrund: The monoclonal antibody 3D5 recognizes complement decay accelerating factor (DAF), also designated as CD55. Cells express on their surface several proteins which protect against complement attack, namely C receptor I (CR1), decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59. CR1, DAF and MCP regulate the activation pathways of complement by either accelerating decay of the C3 and C5 convertase (CR1, DAF), or acting as cofactors for the serine protease factor I, which cleaves and irreversibly inactivates C3b (CR1, MCP). Mouse DAF (CD55) is a 60 kDa transmembrane protein that binds C3b and C4b to inhibit formation and half-life of the C3 convertases. DAF is broadly distributed among cells in contact with serum, including both haematopoietic and nonhaematopoietic cells. Although DAF does not have an essential role in controlling hemolysis of erythrocytes, it has an important role in regulation of the deposition of C3 on nucleated cells. Together with other complement regulators DAF protects self cells from autologous complement- mediated injury. DAF cooperates with CD46 in circumventing autologous C3 deposition, while CD59 inhibits the pathway at the critical end-point. DAF (decay accelerating factor), CD55 Aliases NRK cells expressing transmembrane-anchored mouse DAF Immunogen Rat IgG2a

Pathways: Komplementsystem, Regulation of Leukocyte Mediated Immunity